managing t790-negative egfr-mutated nsclc
Published 7 years ago • 344 plays • Length 13:06Download video MP4
Download video MP3
Similar videos
-
19:28
managing t790-positive egfr-mutated nsclc
-
20:27
managing egfr-resistant disease: t790 and beyond
-
21:35
long term management of egfr-mutant nsclc -tsao
-
24:36
treatment options for egfr t790m negative acquired resistance
-
21:09
mechanisms of resistance to egfr tki and new treatment strategies
-
5:04
gefitinib: inhibitor of egfr tyrosine kinase mutants in nsclc
-
10:15
debbie story: stage 4 lung cancer
-
5:32
introduction to egfr inhibitors
-
19:53
managing progression in egfr-mutant nsclc patients: potential impact of 2nd and 3rd generation tkis?
-
20:35
tki-resistant egfr-mutant nsclc
-
20:24
targeted treatment with egfr tkis: front line options
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
25:04
targeting non-egfr oncologic drivers in nsclc adenocarcinoma
-
23:10
egfr mutation positive tumors: treatment strategies in front line and at relapse
-
20:07
acquired egfr resistance: what are the current therapeutic strategies?
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
17:55
front-line targeted therapy for advanced egfr-positive disease
-
5:01
chemotherapy-tki combinations in metastatic egfr lung cancer
-
4:25
how to understand egfr t790m mutations | dana-farber cancer institute
-
10:05
debate: what is the optimal timing for egfr-targeted therapy? - favor maintenance